Posts

Advancements in CO2 Capture: Core-Membrane Microstructu...

In the face of escalating climate change, the enhancement of carbon dioxide (CO2...

Transforming Visual Speech Representation: The Power of...

In a groundbreaking advancement in the field of machine learning and computer vi...

UCLA Researchers Discover Genetic Markers for Early Det...

In a groundbreaking interview featured in Genomic Press, Dr. Carrie E. Bearden, ...

GCC-4001 by Artiva Biotherapeutics for Rheumatoid Arthr...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently i...

HLC-001 by Human Life CORD Japan for Coronavirus Diseas...

HLC-001 is under clinical development by Human Life CORD Japan and currently in ...

CD19-CD22 CAR-T cells by Shanghai Biomed-Union Biotechn...

CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Bio...

NMDA Regulator by Boehringer Ingelheim International fo...

NMDA Regulator is under clinical development by Boehringer Ingelheim Internation...

Paclitaxel by InnoUp Farma for Solid Tumor: Likelihood ...

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase ...

Fosigotifator by Calico Life Sciences for Unspecified C...

Fosigotifator is under clinical development by Calico Life Sciences and currentl...

Coronavirus Disease 2019 (COVID-19) vaccine by China Na...

Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by Chi...

Abu Dhabi Stem Cells Center develops clinical-grade iPSCs

The Abu Dhabi Stem Cells Center (ADSCC) has developed clinical-grade induced plu...

China’s NMPA approves GSK’s Nucala for CRSwNP treatment

The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment al...

BNT-325 by BioNTech for Malignant Mesothelioma: Likelih...

BNT-325 is under clinical development by BioNTech and currently in Phase II for ...

Age Matters: Enhanced Precision in Kidney Disorder Dete...

Annual health check-ups typically involve routine urine tests, which play a vita...

Extended Paxlovid Treatment Shows Promise for Alleviati...

A near-scrutinizing examination of how patients respond to Paxlovid, particularl...

Neumora shares sink following Phase III flop in MDD

The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to me...